Fig. 2

Prevalence of patients meeting the criteria for metabolic syndrome in tirzepatide-treated patients by weight loss category (< 5%, > 5% to ≤ 10%, > 10% to ≤ 15%, > 15% to ≤ 20%, > 20%). Data are proportion of tirzepatide-treated patients with at least 3 diagnostic criteria for metabolic syndrome at the primary endpoint of 40/52 weeks by weight loss category (< 5%, > 5% to ≤ 10%, > 10% to ≤ 15%, > 15% to ≤ 20%, > 20%). MET: metformin; SGLT2i: sodium-glucose co-transporter 2 inhibitor; SU: sulfonylurea